Introduction to hematopoietic growth factors: a general overview / George Morstyn and MaryAnn Foote -- Animal models of hematopoietic growth factor perturbations in physiology and pathology / Graham J. Lieschke -- The Jak/Stat pathway of cytokine signaling / Ben A. Croker and Nicos A. Nicola -- Small-molecule and peptide agonists: a literature review / Ellen G. Laber and C. Glenn Begley -- Granulocyte colony-stimulating factor / Graham Molineux -- Erythropoietic factors: clinical pharmacology and pharmacokinetics / Steven Elliott, Anne C. Heatherington, and MaryAnn Foote -- Thrombopoietin factors / David J. Kuter -- Stem cell factor and its receptor, c-kit / Keith Langley -- Hematopoietic growth factors: preclinical studies of myeloid and immune reconstitution / Ann M. Farese and Thomas J. MacVittie -- Commentary on the ASCO and ESMO evidence-based clinical practice guidelines for the use of hematopoietic growth factors / Richard M. Fox -- Neutropenia and the problem of fever and infection in patients with cancer / David C. Dale -- Thrombocytopenia and platelet transfusions in patients with cancer / Lawrence T. Goodnough -- Hematopoietic growth factors in lung cancer / Johan F. Vansteenkiste and Christophe A. Dooms -- Role of hematopoietic growth factors as adjuncts to the treatment of Hodgkin's and non-Hodgkin's lymphomas / Marcie R. Tomblyn and Jane N. Winter -- Use of granulocyte growth factors in breast cancer / Eric D. Mininberg and Frankie Ann Holmes -- Role of cytokines in the management of chronic lymphocytic leukemia / Carol Ann Long -- Hematopoietic growth factor therapy for myelodysplastic syndromes and aplastic anemia / Jason Gotlib and Peter L. Greenberg -- Use of hematopoietic growth factors in AIDS-related malignancies / MaryAnn Foote -- The safety profile of hematopoietic growth factors / Roy E. Smith and Barbara C. Good -- Long-term safety of filgrastim in chronic neutropenias / Karl Welte -- Economics of hematopoietic growth factors / Gary H. Lyman and Nicole M. Kuderer -- Potential for hematopoietic growth factor antagonists in oncology / Hayley S. Ramshaw [and others].
0
Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology. Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.
Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
Hematopoietic growth factors in oncology.
1592597475
Cancer-- Chemotherapy.
Hematopoietic growth factors-- Mechanism of action.